GO:0016170 interleukin-15 receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016170 interleukin-15 receptor binding is a molecular function defined as binding to an interleukin-15 receptor.
• IL-15 signals through a receptor complex that includes IL-15RA, IL-2RB and the common gamma chain, and receptor binding is the first step in JAK-STAT activation.
• The IL-15 binding interface on IL-15RA and the IL-15RA-binding site on IL-15 have been mapped by NMR and mutagenesis, providing structural rules for receptor engagement.
• Engineered IL-2/IL-15 mimics and superkines exploit the same receptor-binding principles to tune immune-cell activity.
• IL-15 receptor binding is central to CD8+ T cell and NK cell biology, and dysregulation is linked to inflammatory arthritis and cancer immunotherapy.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal testing of IL-15 receptor-binding interfaces in immune cells and disease models.
Description
GO:0016170 interleukin-15 receptor binding is a molecular function that describes the physical interaction between interleukin-15 (IL-15) and any of its receptor subunits. This binding event is the initiating step for IL-15-dependent signaling, which controls the activation, proliferation and survival of natural killer (NK) cells and memory CD8+ T cells. Because IL-15 receptor binding sits at the top of a clinically important cytokine axis, it is a major target for engineered immunotherapies and for mechanistic studies of inflammatory disease. Researchers study this term to understand how cytokine-receptor affinity, valency and conformational changes translate into downstream JAK-STAT signaling and immune-cell fate. The function is also a benchmark for protein design, because de novo mimics of IL-2 and IL-15 must reproduce the receptor-binding geometry to achieve selective immune activation. In this article, we integrate the QuickGO definition with verified PubMed literature to summarize the mechanism, key genes, disease links and experimental methods for GO:0016170.
interleukin-15 receptor binding At A Glance
| GO ID | GO:0016170 |
|---|---|
| GO term | interleukin-15 receptor binding |
| Ontology | molecular_function |
| Synonym | IL-15; interleukin-15 receptor ligand |
| Definition | Binding to an interleukin-15 receptor. |
| Major function | Initiates IL-15-dependent receptor complex assembly and signaling. |
| Key receptor subunits | IL-15RA, IL-2RB, common gamma chain. |
| Structural basis | Mapped IL-15/IL-15RA interfaces by NMR and mutagenesis. |
| Therapeutic relevance | Target for IL-15 mimics, antagonists and CAR engineering. |
What Is GO:0016170?
According to the QuickGO definition, GO:0016170 interleukin-15 receptor binding is the molecular function of binding to an interleukin-15 receptor. In practice, this means a ligand, typically the cytokine IL-15, makes direct physical contact with one or more receptor subunits, such as IL-15RA, and this interaction can be measured biochemically or structurally. The term is a molecular_function in the Gene Ontology and is synonymous with IL-15 receptor ligand activity.
Why Is interleukin-15 receptor binding Important in Cell Biology?
GO:0016170 is important because IL-15 receptor binding is the gatekeeper for a cytokine pathway that controls NK-cell and CD8+ T-cell immunity, and because engineered versions of this binding event are actively used in cancer immunotherapy and anti-inflammatory drug development. Understanding the exact binding determinants allows researchers to design selective agonists or antagonists, predict off-target signaling, and interpret how mutations in ligand or receptor alter immune responses.
• Defines the first molecular step in IL-15 signaling through IL-15RA, IL-2RB and the common gamma chain.
• Controls NK-cell and memory CD8+ T-cell survival and effector function.
• Provides a structural template for engineering IL-2/IL-15 superkines and mimics.
• Supports development of IL-15 receptor antagonists for inflammatory arthritis.
• Helps explain how PD-1 combination therapy with IL-2 modifies CD8+ T-cell exhaustion programs.
• Enables rational mutation of IL-15 or IL-15RA to test binding specificity.
• Guides CAR-T designs that incorporate JAK-STAT signaling domains.
• Links cytokine-receptor affinity to downstream transcriptional and metabolic programs.
• Offers a benchmark for de novo protein design of selective cytokine mimetics.
• Informs biomarker and target selection in immuno-oncology and autoimmunity.
Molecular Mechanism of interleukin-15 receptor binding
Ligand recognition and initial contact
In simple terms: IL-15 first touches its receptor, like a key finding the right lock.
IL-15 receptor binding begins when the cytokine IL-15 contacts the IL-15 receptor alpha subunit (IL-15RA). This initial recognition is driven by specific surface patches on IL-15, and mutagenesis has identified an IL-15RA-binding site on human IL-15. The interaction is the molecular event captured by GO:0016170 and is required for subsequent receptor complex assembly.
Receptor complex assembly and shared subunits
In simple terms: After the first contact, additional receptor parts join to form a complete signaling machine.
Following IL-15 binding to IL-15RA, the complex recruits IL-2 receptor beta (IL-2RB) and the common gamma chain to form a functional signaling receptor. This shared-subunit architecture explains why IL-15 and IL-2 pathways overlap, and it is the structural basis for JAK-STAT activation. The assembly step is a direct consequence of the binding function annotated as GO:0016170.
Structural determinants of the IL-15/IL-15RA interface
In simple terms: Scientists have mapped exactly which atoms touch each other.
NMR studies have elucidated the interleukin-15 binding site on its alpha receptor, revealing the contact surface that mediates high-affinity interaction. Complementary work identified the IL-15RA-binding site on human IL-15, defining a two-sided interface. These structural data are essential for interpreting how mutations alter GO:0016170 activity and for designing mimics or antagonists.
Conformational tuning and engineered mimics
In simple terms: Small shape changes can make the binding stronger or more selective.
A natural conformational switch was exploited to engineer an IL-2 superkine with enhanced receptor binding, demonstrating that small structural changes can tune cytokine-receptor interactions. De novo design has also produced potent and selective mimics of IL-2 and IL-15 that reproduce the receptor-binding geometry. These studies show that GO:0016170 is not a static event but a tunable molecular recognition process.
Signaling consequences and regulation
In simple terms: Once binding happens, signals travel into the cell and change gene programs.
IL-15 receptor binding leads to JAK-STAT signaling, and a chimeric antigen receptor containing a JAK-STAT signaling domain was shown to mediate superior antitumor effects. PD-1 combination therapy with IL-2 modifies the CD8+ T cell exhaustion program, illustrating how cytokine-receptor signals shape T-cell states. A peptoid IL-15 receptor antagonist can suppress inflammation and arthritis in mice, confirming that blocking this binding function has therapeutic consequences.
Key Genes Involved in GO:0016170 interleukin-15 receptor binding
The following genes and proteins are directly implicated in interleukin-15 receptor binding and its downstream biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL15 | Cytokine ligand that binds the IL-15 receptor | Central to GO:0016170; mutated to map receptor interface. |
| IL15RA | High-affinity receptor alpha subunit for IL-15 | Primary binding partner; NMR-mapped binding site. |
| IL2RB | Shared beta receptor subunit recruited after IL-15 binding | Required for signaling complex assembly. |
| IL2RG | Common gamma chain shared by IL-2 and IL-15 receptors | Essential for JAK-STAT activation. |
| JAK1 | Kinase that propagates signaling from the assembled receptor | Downstream effector of IL-15 receptor binding. |
| JAK3 | Kinase associated with common gamma chain signaling | Contributes to IL-15-dependent STAT activation. |
| STAT5A | Transcription factor activated downstream of IL-15 receptor | Readout of functional receptor binding. |
| STAT5B | Transcription factor activated downstream of IL-15 receptor | Readout of functional receptor binding. |
| PDCD1 | Immune checkpoint receptor modulated in combination therapy | Linked to IL-2/IL-15 signaling and T-cell exhaustion. |
| CD8A | Marker of cytotoxic T cells responding to IL-15 | Used to assess IL-15 receptor binding effects. |
| NKG2D | NK-cell receptor in IL-15-responsive cells | Context for NK-cell studies of IL-15 signaling. |
| FOXP3 | Regulatory T-cell transcription factor | Used to distinguish IL-15 effects on T-cell subsets. |
| GZMB | Granzyme B effector molecule in cytotoxic cells | Functional readout of IL-15 receptor activation. |
| IFNG | Interferon gamma cytokine produced by activated T/NK cells | Functional readout of IL-15 receptor binding. |
| MKI67 | Proliferation marker | Measures IL-15-driven proliferation. |
| BCL2 | Anti-apoptotic protein supporting survival | Survival readout of IL-15 receptor binding. |
| IL2 | Related cytokine that shares receptor subunits | Comparative control for IL-15 receptor binding studies. |
How Is interleukin-15 receptor binding Regulated?
IL-15 receptor binding is regulated at multiple levels. Ligand availability and receptor expression control the probability of encounter, while the shared use of IL-2RB and the common gamma chain means that IL-2 and IL-15 pathways compete for limiting receptor components. Conformational changes in the cytokine can enhance or reduce receptor affinity, as shown by engineered superkines and mimics. Downstream, JAK-STAT signaling provides feedback that shapes T-cell exhaustion programs, and checkpoint pathways such as PD-1 modulate the functional outcome of cytokine-receptor engagement. Pharmacological blockade with a peptoid antagonist demonstrates that the binding event itself can be targeted to suppress inflammation.
interleukin-15 receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL15 | Inflammatory arthritis | IL15 knockout or point-mutant mouse. |
| IL15RA | Autoimmune inflammation | IL15RA knockout or knock-in reporter. |
| IL2RB | Immune dysregulation | IL2RB knockout T-cell lines. |
| PDCD1 | T-cell exhaustion in cancer | PD-1/IL-2 combination in tumor models. |
| JAK1 | Cancer immunotherapy resistance | JAK1 knockout CAR-T models. |
Inflammatory arthritis and autoimmunity
A peptoid interleukin-15 receptor antagonist suppresses inflammation and arthritis in mice, showing that blocking GO:0016170 activity can reduce disease severity. This links IL-15 receptor binding directly to inflammatory joint pathology and supports antagonist development for autoimmune conditions.
Cancer immunotherapy and T-cell exhaustion
IL-15 receptor binding contributes to CD8+ T-cell and NK-cell activation, and PD-1 combination therapy with IL-2 modifies the CD8+ T cell exhaustion program, indicating that cytokine-receptor signals influence exhaustion states. CAR constructs containing JAK-STAT signaling domains mediate superior antitumor effects, further connecting this pathway to cancer therapy.
Engineered cytokine therapeutics
De novo designed mimics of IL-2 and IL-15 and engineered superkines exploit receptor-binding principles to achieve selective immune activation. These designs depend on precise knowledge of the IL-15/IL-15RA interface and demonstrate the translational value of studying GO:0016170.
From interleukin-15 receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of IL-15 receptor binding reduce immune activation? | IL15 or IL15RA knockout cell lines and mice. |
| Which residues mediate IL-15/IL-15RA contact? | Point-mutation knock-in of IL15 or IL15RA. |
| Can a designed mimic reproduce IL-15 receptor binding? | Knock-in or overexpression of engineered IL-15 mimics. |
| How does receptor binding affect downstream STAT5? | Tagged knock-in of STAT5 or reporter assays. |
| Does blocking binding suppress arthritis? | IL-15 receptor antagonist in mouse arthritis models. |
| How does PD-1 modulate IL-15/IL-2 responses? | PDCD1 knockout or overexpression in T cells. |
How to Study the interleukin-15 receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics | IL-15/IL-15RA interaction. |
| NMR spectroscopy | Residue-level binding interface | Mapping IL-15 binding site. |
| Mutagenesis | Functional importance of residues | Identifying IL-15RA-binding site. |
| Phospho-STAT5 flow | JAK-STAT activation | Receptor signaling readout. |
| RNA-seq | Transcriptional programs | T-cell exhaustion analysis. |
| CRISPR knockout | Gene requirement | Testing IL15/IL15RA necessity. |
| Reporter assays | Pathway activity | Screening cytokine mimics. |
| Mouse arthritis models | In vivo inflammation | Testing IL-15 antagonists. |
Binding assays and structural biology
Surface plasmon resonance, isothermal titration calorimetry and NMR can directly measure IL-15 receptor binding affinity and map interfaces. These methods are the primary way to assign GO:0016170 activity to a specific ligand-receptor pair.
Cell-based signaling readouts
Phospho-STAT5 flow cytometry, luciferase reporters and cytokine production assays measure the functional consequence of IL-15 receptor binding. These readouts connect molecular binding to JAK-STAT pathway activation.
Genetic perturbation and CRISPR screens
CRISPR knockout, point mutation and knock-in models allow causal testing of IL15, IL15RA, IL2RB and JAK genes in immune cells. Pooled screens can identify modifiers of IL-15-dependent proliferation and survival.
Transcriptomics and functional genomics
RNA-seq and single-cell transcriptomics reveal how IL-15 receptor binding reshapes T-cell exhaustion and effector programs. These datasets help interpret the downstream consequences of receptor engagement.
How CRISPR Can Be Used to Study GO:0016170 interleukin-15 receptor binding
Knockout
CRISPR knockout of IL15, IL15RA, IL2RB or JAK genes removes the receptor-binding axis and provides a clean loss-of-function background to test whether a phenotype depends on GO:0016170. Knockout models are also used to validate antagonist effects in inflammatory disease.
Point Mutation
Point mutations at the IL-15/IL-15RA interface can selectively disrupt binding without deleting the entire protein, allowing fine mapping of residues required for GO:0016170. Such mutants are valuable for distinguishing binding defects from folding or expression defects.
Knock-in
Knock-in of tagged or reporter alleles enables tracking of receptor expression and signaling in primary immune cells. Knock-in of engineered IL-15 variants can test whether designed mimics reproduce native receptor binding.
Overexpression
Overexpression of IL-15, IL-15RA or constitutively active JAK-STAT constructs can amplify receptor-binding signals and reveal gain-of-function phenotypes in T cells and NK cells. This approach is useful for studying exhaustion programs and antitumor activity.
How EDITGENE Supports interleukin-15 receptor binding Research
Researchers studying interleukin-15 receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor engagement, downstream signaling or immune-cell phenotypes. EDITGENE provides CRISPR-based cell models and screening services that make these causal tests reproducible and scalable.
Contact EDITGENE today to design your custom CRISPR model for interleukin-15 receptor binding research.
Frequently Asked Questions About interleukin-15 receptor binding
What is GO:0016170 interleukin-15 receptor binding?
GO:0016170 is a molecular function defined as binding to an interleukin-15 receptor, typically by the cytokine IL-15.
What genes are involved in interleukin-15 receptor binding?
Key genes include IL15, IL15RA, IL2RB, IL2RG, JAK1, JAK3, STAT5A and STAT5B.
Which receptor subunits does IL-15 bind?
IL-15 binds IL-15RA and then recruits IL-2RB and the common gamma chain to form a signaling complex.
How is IL-15 receptor binding studied experimentally?
Common methods include surface plasmon resonance, NMR, mutagenesis, phospho-STAT5 flow cytometry and CRISPR perturbation.
Why is IL-15 receptor binding important in cancer immunotherapy?
It drives NK-cell and CD8+ T-cell activation, and engineered mimics or CAR designs exploit this pathway for antitumor effects.
Can IL-15 receptor binding be blocked therapeutically?
Yes, a peptoid IL-15 receptor antagonist has been shown to suppress inflammation and arthritis in mice.
What is the difference between IL-2 and IL-15 receptor binding?
Both cytokines share IL-2RB and the common gamma chain, but IL-15 has a distinct high-affinity alpha receptor, IL-15RA.
Which residues mediate IL-15 binding to IL-15RA?
NMR and mutagenesis studies have mapped the IL-15 binding site on IL-15RA and the IL-15RA-binding site on IL-15.
How does IL-15 receptor binding affect T-cell exhaustion?
Cytokine-receptor signals, including IL-2/IL-15 pathways, modify CD8+ T cell exhaustion programs in combination with checkpoint blockade.
What CRISPR models are useful for studying GO:0016170?
Knockout, point-mutation, knock-in and overexpression models of IL15, IL15RA and downstream JAK-STAT genes are all useful.
Conclusion
GO:0016170 interleukin-15 receptor binding is a well-defined molecular function that initiates IL-15-dependent immune signaling through IL-15RA, IL-2RB and the common gamma chain. Structural and engineering studies have mapped the binding interface and shown that it can be tuned or blocked for therapeutic benefit. CRISPR-based knockout, point-mutation, knock-in and overexpression models provide the causal toolkit needed to connect this binding event to immune-cell phenotypes and disease.
References
- 1. Cho KB et al.. 2022. A peptoid interleukin-15 receptor antagonist suppresses inflammation and arthritis in mice.. Clin Transl Immunology 11(11):e1432 PMID: 36439637
- 2. Cosman D et al.. 1995. Interleukin 15 and its receptor.. Ciba Found Symp 195:221-9; discussion 229-33 PMID: 8724840
- 3. Hashimoto M et al.. 2022. PD-1 combination therapy with IL-2 modifies CD8(+) T cell exhaustion program.. Nature 610(7930):173-181 PMID: 36171288
- 4. Silva DA et al.. 2019. De novo design of potent and selective mimics of IL-2 and IL-15.. Nature 565(7738):186-191 PMID: 30626941
- 5. Levin AM et al.. 2012. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.. Nature 484(7395):529-33 PMID: 22446627
- 6. Kagoya Y et al.. 2018. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.. Nat Med 24(3):352-359 PMID: 29400710
- 7. Hanick NA et al.. 2007. Elucidation of the interleukin-15 binding site on its alpha receptor by NMR.. Biochemistry 46(33):9453-61 PMID: 17655329
- 8. Bernard J et al.. 2004. Identification of an interleukin-15alpha receptor-binding site on human interleukin-15.. J Biol Chem 279(23):24313-22 PMID: 15039446
